These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

173 related articles for article (PubMed ID: 27798550)

  • 1. Bone Age and Mineral Density Assessments Using Plain Roentgenograms in Tenofovir-exposed Infants in Malawi and Brazil Enrolled in HIV Prevention Trials Network 057.
    Osorio LE; Boechat MI; Mirochnick M; Kumwenda N; Kreitchmann R; Emel L; Pinto J; Joao E; Santos B; Swenson M; George K; Sato P; Mofenson L; Nielsen-Saines K;
    Pediatr Infect Dis J; 2017 Feb; 36(2):184-188. PubMed ID: 27798550
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Meconium Tenofovir Concentrations and Growth and Bone Outcomes in Prenatally Tenofovir Exposed HIV-Uninfected Children.
    Himes SK; Wu JW; Jacobson DL; Tassiopoulos K; Hazra R; Kacanek D; Van Dyke RB; Rich KC; Siberry GK; Huestis MA;
    Pediatr Infect Dis J; 2015 Aug; 34(8):851-7. PubMed ID: 25961889
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pharmacokinetics and safety of tenofovir in HIV-infected women during labor and their infants during the first week of life.
    Mirochnick M; Taha T; Kreitchmann R; Nielsen-Saines K; Kumwenda N; Joao E; Pinto J; Santos B; Parsons T; Kearney B; Emel L; Herron C; Richardson P; Hudelson SE; Eshleman SH; George K; Fowler MG; Sato P; Mofenson L;
    J Acquir Immune Defic Syndr; 2014 Jan; 65(1):33-41. PubMed ID: 23979002
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Lower Newborn Bone Mineral Content Associated With Maternal Use of Tenofovir Disoproxil Fumarate During Pregnancy.
    Siberry GK; Jacobson DL; Kalkwarf HJ; Wu JW; DiMeglio LA; Yogev R; Knapp KM; Wheeler JJ; Butler L; Hazra R; Miller TL; Seage GR; Van Dyke RB; Barr E; Davtyan M; Mofenson LM; Rich KC;
    Clin Infect Dis; 2015 Sep; 61(6):996-1003. PubMed ID: 26060285
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Safety of tenofovir during pregnancy: early growth outcomes and hematologic side effects in HIV-exposed uninfected infants.
    Seidel V; Weizsäcker K; Henrich W; Rancourt RC; Bührer C; Krüger R; Feiterna-Sperling C
    Eur J Pediatr; 2020 Jan; 179(1):99-109. PubMed ID: 31659467
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Growth and Neurodevelopment Outcomes in HIV-, Tenofovir-, and Efavirenz-Exposed Breastfed Infants in the PMTCT Option B+ Program in Malawi.
    Kapito-Tembo AP; Bauleni A; Wesevich A; Ongubo D; Hosseinipour MC; Dube Q; Mwale P; Corbett A; Mwapasa V; Phiri S
    J Acquir Immune Defic Syndr; 2021 Jan; 86(1):81-90. PubMed ID: 33027153
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Impact of postpartum tenofovir-based antiretroviral therapy on bone mineral density in breastfeeding women with HIV enrolled in a randomized clinical trial.
    Stranix-Chibanda L; Tierney C; Sebikari D; Aizire J; Dadabhai S; Zanga A; Mukwasi-Kahari C; Vhembo T; Violari A; Theron G; Moodley D; George K; Fan B; Sommer MJ; Browning R; Mofenson LM; Shepherd J; Nelson B; Fowler MG; Siberry GK;
    PLoS One; 2021; 16(2):e0246272. PubMed ID: 33544759
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Maternal Tenofovir Disoproxil Fumarate Use in Pregnancy and Growth Outcomes among HIV-Exposed Uninfected Infants in Kenya.
    Pintye J; Langat A; Singa B; Kinuthia J; Odeny B; Katana A; Nganga L; John-Stewart G; McGrath CJ
    Infect Dis Obstet Gynecol; 2015; 2015():276851. PubMed ID: 26823647
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Tenofovir disoproxil fumarate safety for women and their infants during pregnancy and breastfeeding.
    Mofenson LM; Baggaley RC; Mameletzis I
    AIDS; 2017 Jan; 31(2):213-232. PubMed ID: 27831952
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Safety of Tenofovir Disoproxil Fumarate-Based Antiretroviral Therapy Regimens in Pregnancy for HIV-Infected Women and Their Infants: A Systematic Review and Meta-Analysis.
    Nachega JB; Uthman OA; Mofenson LM; Anderson JR; Kanters S; Renaud F; Ford N; Essajee S; Doherty MC; Mills EJ
    J Acquir Immune Defic Syndr; 2017 Sep; 76(1):1-12. PubMed ID: 28291053
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Tenofovir Disoproxil Fumarate Use during Pregnancy and Infant Bone Health: the Tenofovir in Pregnancy Pilot Study.
    Kourtis AP; Wiener J; Wang L; Fan B; Shepherd JA; Chen L; Liu W; Shepard C; Wang L; Wang A; Bulterys M
    Pediatr Infect Dis J; 2018 Nov; 37(11):e264-e268. PubMed ID: 30067600
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Influence of maternal use of tenofovir disoproxil fumarate or zidovudine in Vietnamese pregnant women with HIV on infant growth, renal function, and bone health.
    Kinai E; Nguyen HDT; Do HQ; Matsumoto S; Nagai M; Tanuma J; Nguyen KV; Pham TN; Oka S
    PLoS One; 2021; 16(4):e0250828. PubMed ID: 33914827
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Safety and efficacy of Option B+ ART in Malawi: few severe maternal toxicity events or infant HIV infections among pregnant women initiating tenofovir/lamivudine/efavirenz.
    Harrington BJ; DiPrete BL; Jumbe AN; Ngongondo M; Limarzi L; Wallie SD; Chagomerana MB; Hosseinipour MC;
    Trop Med Int Health; 2019 Oct; 24(10):1221-1228. PubMed ID: 31381233
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pharmacokinetics and safety of single-dose tenofovir disoproxil fumarate and emtricitabine in HIV-1-infected pregnant women and their infants.
    Flynn PM; Mirochnick M; Shapiro DE; Bardeguez A; Rodman J; Robbins B; Huang S; Fiscus SA; Van Rompay KK; Rooney JF; Kearney B; Mofenson LM; Watts DH; Jean-Philippe P; Heckman B; Thorpe E; Cotter A; Purswani M;
    Antimicrob Agents Chemother; 2011 Dec; 55(12):5914-22. PubMed ID: 21896911
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Birth Outcomes for Pregnant Women with HIV Using Tenofovir-Emtricitabine.
    Rough K; Seage GR; Williams PL; Hernandez-Diaz S; Huo Y; Chadwick EG; Currier JS; Hoffman RM; Barr E; Shapiro DE; Patel K;
    N Engl J Med; 2018 Apr; 378(17):1593-1603. PubMed ID: 29694825
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Safety of tenofovir use during pregnancy: early growth outcomes in HIV-exposed uninfected infants.
    Siberry GK; Williams PL; Mendez H; Seage GR; Jacobson DL; Hazra R; Rich KC; Griner R; Tassiopoulos K; Kacanek D; Mofenson LM; Miller T; DiMeglio LA; Watts DH;
    AIDS; 2012 Jun; 26(9):1151-9. PubMed ID: 22382151
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Tenofovir disoproxil fumarate in pregnancy and prevention of mother-to-child transmission of HIV-1: is it time to move on from zidovudine?
    Foster C; Lyall H; Olmscheid B; Pearce G; Zhang S; Gibb DM
    HIV Med; 2009 Aug; 10(7):397-406. PubMed ID: 19459986
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pregnancy and infant outcomes among HIV-infected women taking long-term ART with and without tenofovir in the DART trial.
    Gibb DM; Kizito H; Russell EC; Chidziva E; Zalwango E; Nalumenya R; Spyer M; Tumukunde D; Nathoo K; Munderi P; Kyomugisha H; Hakim J; Grosskurth H; Gilks CF; Walker AS; Musoke P;
    PLoS Med; 2012; 9(5):e1001217. PubMed ID: 22615543
    [TBL] [Abstract][Full Text] [Related]  

  • 19. In Utero Tenofovir Exposure Is not Associated With Fetal Long Bone Growth.
    Jao J; Abrams EJ; Phillips T; Petro G; Zerbe A; Myer L
    Clin Infect Dis; 2016 Jun; 62(12):1604-1609. PubMed ID: 27009251
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Growth indices in breastfed infants pre and postnatally exposed to tenofovir compared with tenofovir-unexposed infants.
    Liotta G; Floridia M; Andreotti M; Jere H; Sagno JB; Marazzi MC; Buonomo E; Scarcella P; Mancinelli S; Vella S; Giuliano M; Palombi L
    AIDS; 2016 Jan; 30(3):525-7. PubMed ID: 26765942
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.